switching between glp-1 agonists ada RA education PDF] Switching Between Glucagon-Like Peptide-1

Yeah, that statement is a definite downer

2011;17(12):CR677CR682

It consists of a sequence of five amino acids

We see this with other medications

The availability of oral formulations addresses patient preferences for non-injectable medications while the entry of additional manufacturers beyond the current duopoly is expected to improve supply availability and create pricing competition that will facilitate broader access

Because NMDA-R hypofunction (for example in GABAergic interneurons) has presumed down-stream effects (dis-inhibition of pyramidal cells) with increased glutamatergic neurotransmission and possible neurotoxicity, low affinity NMDA-R antagonism has been an alternative approach (memantine, riluzole)